A detailed history of Securian Asset Management, Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Securian Asset Management, Inc holds 9,850 shares of HALO stock, worth $531,506. This represents 0.02% of its overall portfolio holdings.

Number of Shares
9,850
Previous 10,151 2.97%
Holding current value
$531,506
Previous $531,000 6.03%
% of portfolio
0.02%
Previous 0.02%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$51.3 - $64.42 $15,441 - $19,390
-301 Reduced 2.97%
9,850 $563,000
Q2 2024

Jul 15, 2024

SELL
$37.81 - $52.4 $26,656 - $36,942
-705 Reduced 6.49%
10,151 $531,000
Q1 2024

Apr 26, 2024

SELL
$33.68 - $41.95 $7,308 - $9,103
-217 Reduced 1.96%
10,856 $441,000
Q4 2023

Feb 08, 2024

SELL
$33.32 - $42.1 $3,332 - $4,210
-100 Reduced 0.9%
11,073 $409,000
Q3 2023

Oct 30, 2023

SELL
$36.46 - $44.03 $20,308 - $24,524
-557 Reduced 4.75%
11,173 $426,000
Q2 2023

Aug 07, 2023

SELL
$30.28 - $38.74 $17,683 - $22,624
-584 Reduced 4.74%
11,730 $423,000
Q1 2023

Apr 27, 2023

SELL
$32.86 - $55.7 $3,647 - $6,182
-111 Reduced 0.89%
12,314 $470,000
Q4 2022

Feb 02, 2023

SELL
$40.06 - $59.44 $4,286 - $6,360
-107 Reduced 0.85%
12,425 $706,000
Q2 2022

Aug 04, 2022

SELL
$37.35 - $48.3 $3,735 - $4,830
-100 Reduced 0.79%
12,532 $551,000
Q1 2022

May 03, 2022

BUY
$31.97 - $41.06 $735 - $944
23 Added 0.18%
12,632 $504,000
Q4 2021

Feb 10, 2022

SELL
$31.82 - $40.75 $4,932 - $6,316
-155 Reduced 1.21%
12,609 $507,000
Q3 2021

Nov 08, 2021

BUY
$38.47 - $46.42 $17,850 - $21,538
464 Added 3.77%
12,764 $519,000
Q2 2021

Aug 10, 2021

BUY
$38.84 - $51.31 $13,788 - $18,215
355 Added 2.97%
12,300 $559,000
Q1 2021

May 10, 2021

SELL
$39.51 - $51.45 $3,951 - $5,145
-100 Reduced 0.83%
11,945 $498,000
Q4 2020

Feb 08, 2021

BUY
$25.81 - $43.62 $310,881 - $525,402
12,045 New
12,045 $514,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.52B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Securian Asset Management, Inc Portfolio

Follow Securian Asset Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Securian Asset Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Securian Asset Management, Inc with notifications on news.